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Abstract
Interleukin (IL)-17 is emerging as an important cytokine in vaccine-induced protection against tuberculosis disease in animal
models. Here we show that compared to parenteral delivery, BCG delivered mucosally enhances cytokine production,
including interferon gamma and IL-17, in the lungs. Furthermore, we find that cholera toxin, delivered mucosally along with
BCG, further enhances IL-17 production by CD4+ T cells over mucosal BCG alone both in the lungs and systemically. This
boosting effect of CT is also observed using a vaccine regimen of BCG followed by the candidate vaccine MVA85A. Using a
murine Mycobacterium tuberculosis (M.tb) aerosol challenge model, we demonstrate the ability of cholera toxin delivered at
the time of a priming BCG vaccination to improve protection against tuberculosis disease in a manner at least partially
dependent on the observed increase in IL-17. This observed increase in IL-17 in the lungs has no adverse effect on lung
pathology following M.tb challenge, indicating that IL-17 can safely be boosted in murine lungs in a vaccine/M.tb challenge
setting.
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Introduction
Tuberculosis (TB) remains a major global health threat, with an
annual worldwide incidence of approximately nine million [1].
The only licensed vaccine, Bacille Calmette Gue´rin (BCG), is
currently administered at birth throughout most of the world,
however its efficacy, particularly in TB endemic countries, is
highly variable [2]. There is therefore an urgent need for a more
effective TB vaccine regimen. Protection against TB disease is
known to depend at least partially on interferon (IFN)-c, although
it is clear that a strong IFN-c-based T cell response is not sufficient
to confer complete protection. Interleukin (IL)-17 is emerging as
an important cytokine in vaccine-induced protection against TB
disease in both mice [3,4] and cattle [5]. Work in murine TB
models has found that IL-17 expression in the lungs mediates the
formation of lymphocytic granulomas through inducing the
upregulation of the chemokine ligand CXCL13 and thus the
recruitment of highly activated T cells bearing the CXCL13
receptor, CXCR5 [6]. Although its importance in humans is not
yet known, IL-17 is readily detectable as a product of T cells
isolated from both bronchoalveolar lavage fluid and pleural fluid
from patients with active TB [7–10].
MVA85A is a modified Vaccinia virus Ankara expressing the
mycobacterial antigen 85A (Ag85A). The MVA85A vaccine is
used to boost CD4+ T cell responses primed by BCG vaccination
[11]. The vaccine has been administered to over 3000 humans
over the course of the past decade, with good safety and high levels
of antigen-specific T cells induced in adults. The vaccinated
groups include adults in the UK and in the Gambia, South Africa
and Senegal, as well as individuals with latent TB infection,
adolescents, infants and HIV-infected adults. A Phase IIb efficacy
trial of MVA85A in South African infants has recently been
completed [12], and a second Phase IIb trial in HIV-infected
adults in South Africa and Senegal is currently underway
(ClinicalTrials.gov identifier: NCT01151189). Results from the
efficacy trial in infants showed no difference in TB incidence
between infants vaccinated with BCG alone or BCG followed by
MVA85A [13], however given that the IFN- c responses in infants
were lower than those observed in adults, continued work on
MVA85A is warranted with potential in populations where
immunity is higher. The primary readout for immunogenicity is
IFN-c production measured by ELISpot, which has been shown to
be produced predominantly by CD4+ T cells [11]. Analysis of
cytokine expression in both whole blood and PBMC from
vaccinees by flow cytometry has also shown induction of IL-2,
TNF-a and IL-17 in CD4+ T cells by MVA85A [14–16].
Cholera toxin (CT), produced by the bacterium Vibrio cholerae, is
a potent IL-17-inducing adjuvant, which acts through the cyclic
adenosine monophosphate (cAMP) pathway. It exists as a
holotoxin, with a pentameric B subunit that binds to the
ganglioside GM1 on the cell surface. This binding facilitates
translocation of the A subunit through the endoplasmic reticulum
and into the cytosol where it binds ADP ribosylation factor 6,
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which ribosylates adenylyl cyclase (AC), rendering it constitutively
active, resulting in increased levels of cAMP in the cytosol and
therefore an increase in events downstream of cAMP [17]. With
respect to modulation of the immune function of cells, CT has
been shown to have a direct negative effect on IL-12 production
by preventing binding of IRF (interferon regulatory factor) 8 to the
IL-12p40 promoter in dendritic cells (DCs) [18]. Furthermore,
increased intracellular cAMP in DCs, induced either through CT
treatment or through administration of the cell-permeable
dibutyryl cAMP or the cAMP-inducing agent forskolin, increased
IL-17 production by CD4+ T cells following culture with the
treated DCs and was found to act through the protein kinase A
(PKA) pathway [19], inducing IL-17 in an IL-6 and IL-1b-
dependent manner. CT has previously been used as an adjuvant in
murine models and been shown to be a potent inducer of IL-17,
conferring protection against IL-17-dependent diseases [19,20].
A CT-like toxin, Escherichia coli’s heat labile toxin, has been used
in a human vaccine trial as an adjuvant for intranasally-delivered
vaccines against M.tb and HIV. The trial had to be terminated,
however, due to the development of a Bell’s palsy in two of the
volunteers [21]. CT cannot therefore be used as an adjuvant in
human vaccines, however alternatives that target the cAMP
pathway could be evaluated.
Here, we aim to investigate the potential for a BCG – MVA85A
vaccine regime to induce IL-17 in a model murine system in order
to then investigate how boosting IL-17 might affect M.tb challenge
outcome. We show that BCG – MVA85A delivered intranasally
does indeed induce IL-17 both mucosally and systemically and
that CT can enhance IL-17 production when administered
together with BCG. When challenged with M.tb, these mice are
better protected than those not receiving CT, suggesting that the
cAMP pathway induces responses important for protection against
TB disease.
Materials and Methods
Animals and vaccinations
All animal experiments were carried out in accordance with the
guidelines set out by the UK Home Office in the Animals
(Scientific Procedures) Act 1986 and were approved under the
Jenner Institute project license 30/2889. Experiments were carried
out under the personal license 30/8774. Maximum care was taken
to ensure minimal suffering.
Six to eight week old Balb/c mice were obtained from Harlan,
UK.
BCG Pasteur (passaged in-house) was administered at
46105 CFU/vaccination. MVA85A was administered at
16106 PFU/vaccination. Cholera toxin (List Labs; Campbell,
USA) was administered at 2 mg/mouse in 50 mL mixed with the
vaccine.
The anti-IL-17A blocking antibody (MAB421) and its corre-
sponding IgG2a isotype control (MAB006), both from R&D
Systems (Minneapolis, USA), were administered intraperitoneally
(i.p.) at 100 mg/mouse in 100 mL every three days following
challenge for four weeks.
For intranasal (i.n.) vaccination, animals were sedated using
IsoFlo (Oxford University Veterinary Services; UK) and the
vaccine administered in a 50 mL bolus using a pipette held over
the nose.
Intradermal (i.d.) vaccinations of 25 mL into each ear dorsum
using a U-100 29G needle were administered under IsoFlo
anaesthesia.
Intraperitoneal administration of substances was done on
restrained animals and delivered in 100 mL using a 1 mL syringe
with a 29G needle.
M.tb aerosol challenge
Animals were challenged using a Biaera AeroMP-controlled
nebuliser contained in a Category Level 3 TCOL isolator.
Erdmann M.tb (BEI Resources; Manassas, USA)) was made up
to 56106 CFU/mL in PBS and transferred to the nebuliser in the
isolator. Animals were loaded into nose-only restrainers and fitted
to the exposure unit. The programme was run for 10 min plus a
5 min purge with the airflow set to 12 L/min at a pressure of
20psig. The target dose of 100–200 CFU/animal was confirmed
by sacrificing two unvaccinated animals from each run 24 hours
post-challenge.
Organ harvest and stimulation for immunogenicity
For immunogenicity studies, spleens and lungs were aseptically
removed. Prior to dissection, lungs were perfused using 5 mL PBS
passed through the right ventricle. Spleens were passed through a
70 mm sieve into 5 mL Dulbecco’s modified Eagle Medium
(Sigma Aldrich; St Louis, USA) supplemented with 2 mM L-
glutamine and 100 U Penicillin/100 mg Streptomycin (both from
Sigma Aldrich) and transferred to a 15 mL tube. Splenocytes were
treated with red blood cell lysis buffer.
Lungs were minced and digested using a DNase/collagenase
mix containing 1.4 mg/mL collagenase (Sigma Aldrich) and 60 mg
DNase (Sigma Aldrich), followed by red blood cell lysis.
Cells were plated in a round bottom 96 well plate and an Ag85A
peptide pool or PPD added to the relevant wells to give a final
concentration of 2 mg/mL for the peptides and 10 mg/mL for the
PPD. Brefeldin A (Sigma Aldrich; 25 mg/well) and 0.7 mL/well
GolgiStop (BD Pharmingen; Franklin Lakes, USA) were added
two hours after the addition of the antigen and cells were
stimulated for a further 16 hours.
Following stimulation, cells were stained with Live/Dead
Fixable Dead Cell Stain (Invitrogen; Grand Island, USA) followed
by a surface staining cocktail, including antibodies (all from
eBioscience (San Diego, USA) except where indicated) against
CD4-Qdot605 (Invitrogen; GK1.5), B220-PE-Texas Red (RA3-
6B2) and CD19-Pacific Blue (eBio1D3). Following permeabilisa-
tion using CytoFix/CytoPerm (BD Biosciences), cells were stained
intracellularly for analysis of cytokine production. Antibodies for
intracellular staining included CD3-PE-Cy5 (145-2C11), CD8-
APC-AlexaFluor780 (53–6.7), IFN-c-AlexaFluor488 (XMG1.2)
and IL-17A-PE (eBio17B7). Samples were analysed using an LSR
II flow cytometer and data processed using FlowJo (TreeStar;
Ashland, USA).
Organ harvest for bacterial load quantitation
Lungs and spleens removed from challenged animals were
placed in reinforced 2 mL tubes containing 2.8 mm ceramic beads
(Stretton Scientific; Stretton, UK)). Organs were homogenised at
5500 rpm for 20 seconds using a Precellys 24 (Stretton Scientific)
tissue homogeniser before diluting and plating on Middlebrook
7H10 agar plates. Plates were counted four weeks after plating.
Plates were made using Middlebrook 7H10 Agar Base (Sigma
Aldrich) with 2.5 mL glycerol added/500 mL. After autoclaving
for sterilisation, 50 mL OADC (BD Diagnostic Systems) enrich-
ment was added/500 mL and plates poured at 15–20 mL agar/
plate.
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Organ preparation for histology
For histology, animals were sacrificed by cervical dislocation.
Spleen and the other lung lobe were removed and placed in tubes
as described above for CFU quantitation. A hole was cut in the
trachea using a blade and 500 mL 10% Neutral Buffered Formalin
(NBF; Sigma Aldrich) injected using 0.3 mm60.6 mm tubing
attached to a 23G needle on a 2 mL syringe. The lung was
removed and placed in 7.5 mL 10% NBF overnight. The
following day the lobes were transferred to 70% ethanol and
stored at 4uC. Embedding, sectioning, and haematoxylin and
eosin (H&E) staining were performed by Histopathox (Oxford,
UK).
Analysis of lung sections
Stained sections were scanned by the Oxford Centre for
Histopathology Research (OCHRe; Oxford, UK) at620 magni-
fication using a Hamamatsu slide scanner. Files were provided as
.ndpi files, which were converted to .tif files using the ndip2tiff
software provided by Dr Christophe Deroulers (NDPITools;
http://www.imnc.in2p3.fr/pagesperso/deroulers/software/
ndpitools/) [22]. The k means clustering algorithm in MATLAB
(MATLAB 7.13.0, The MathWorks Inc., Natick, USA http://
www.mathworks.com.au/help/stats/kmeans.html) was used to
determine exclusive k means clustering of three colours (white,
pink and purple) in the haematoxylin and eosin-stained tissue.
Each cluster (colour) was further defined by selecting 10 hues for
each. This produced a representative image composed of only the
three colours selected, with each pixel being assigned to one of the
three colours. Finally, a statistical module was programmed in
order to determine the percentage contribution of each cluster to
the overall image by counting the number of pixels belonging to
each colour group.
Statistical analyses
Analysis of two data sets was performed using a t test
(parametric) or Mann-Whitney test (non-parametric). One way
ANOVA was used for comparing three or more groups of
normally distributed data followed by post-hoc tests. Analyses were
performed using statistical analysis tools in GraphPad Prism
version 5.0 for Mac OSX.
Results
Intranasal delivery of BCG + CT enhances IL-17 and
improves vaccine efficacy following M.tb challenge
As previously reported, in mouse models of TB disease,
intranasal (i.n.) delivery of BCG improves protection against M.tb
challenge compared to intradermal (i.d.) delivery [23–26]. As
shown in Figure 1B, using a vaccine regimen of BCG followed by
MVA85A (BCG – MVA85A) we have found that i.n. vaccination
enhances overall cytokine production in the lungs compared to i.d.
vaccination. Furthermore, production of IL-17 by CD4+ T cells in
lungs is enhanced following i.n. BCG and MVA85A boost (Fig 1B).
We have therefore based the experiments shown in this paper on
i.n. delivery of the vaccine. Sample flow plots for lungs and spleen
are shown in Figure 1A.
In order to investigate the effect of CT on BCG immunoge-
nicity, Balb/c mice were vaccinated with BCG i.n. Half the
animals received CT (2 mg/mouse) co-administered with the
BCG. Lungs and spleen were taken 10 weeks post-vaccination and
responses to purified protein derivative (PPD) determined by
intracellular cytokine staining (ICS). Balb/c mice were chosen due
to the existence of an I-Ad-restricted epitope (p15) in Ag85A for
later experiments involving MVA85A; furthermore, their relative
resistance to M.tb infection allows establishment of a long-term
infection.
Production of IFN-c by CD4+ T cells in either lungs (Fig 1C) or
spleen (Fig 1D) was not affected by CT treatment. Percentages of
cells producing IL-17 in both lungs and spleen, however, were
significantly increased in the group receiving BCG + CT (Fig 1C &
D; p = 0.0317 and 0.0159 for lung and spleen respectively).
Percentages of CD4+ T cells simultaneously producing IFN-c and
IL-17 in the lungs, but not spleen, were significantly increased
following CT treatment (p = 0.0079).
These vaccination regimens were further investigated in an M.tb
aerosol challenge model in order to evaluate the effect of CT on
vaccine-induced protection following M.tb exposure. Balb/c mice
vaccinated with BCG6CT i.n. were challenged with M.tb via
aerosol 10 weeks post-BCG. Lung and spleen bacterial burdens
(measured in colony forming units (CFU)) were determined four
weeks post-challenge. As shown in Figure 1E, results following
M.tb challenge confirmed BCG-conferred protection (mean (log10)
= 7.07 and 5.71 CFU/lung for naı¨ve and BCG i.d. respectively,
p,0.0001). Delivery of BCG i.n. improved protection in the lungs
compared to BCG i.d. (mean (log10) = 5.71 and 4.83 CFU/lung
for BCG i.d. and i.n. respectively, p = 0.0001). Similar results were
observed in the spleen. Administration of CT together with BCG
i.n. improved protection in the lungs further (mean (log10) = 4.83
and 3.83 CFU/lung for BCG i.n. and BCG + CT i.n. respectively,
p,0.0001).
Intranasal delivery of BCG + CT – MVA85A enhances IL-17
and improves efficacy following M.tb challenge
In order to investigate the ability of the novel TB vaccine
MVA85A to further boost the enhanced IL-17 responses observed
following BCG + CT administration i.n., Balb/c mice were
vaccinated with BCG6CT i.n. followed 10 weeks later by
MVA85A i.n.
As observed for BCG + CT alone, boosting further with
MVA85A (BCG + CT – MVA85A) did not significantly change
percentages of IFN-c-producing CD4+ T cells in the lungs (Fig 2A)
or spleen (Fig 2B) compared to animals receiving only BCG –
MVA85A, although there was a trend towards higher percentages
of IFN-c+ cells in animals receiving CT. Percentages of CD4+ T
cells producing IL-17, in contrast, were significantly higher in
animals vaccinated with BCG + CT – MVA85A compared to
those receiving BCG – MVA85A (p = 0.0068 and 0.0021 at 11
and 14 weeks post-BCG respectively in lungs, and p = 0.0017 and
0.0362 at 11 and 14 weeks post-BCG respectively in spleen). For
IFN-c+IL-17+ cells, a significant increase following CT treatment
was observed one week post-MVA85A (11 weeks post-BCG) in the
lungs and the spleen (p = 0.0068 and 0.015 for lungs and spleen
respectively). This was not detectable four weeks post-MVA85A.
Animals receiving the vaccine regimens described above were
challenged with aerosolised M.tb four weeks post-MVA85A in
order to investigate whether CT could enhance vaccine efficacy
conferred by BCG – MVA85A. As shown in Figure 2C, BCG i.d.
conferred the expected 1 – 2 log protection against TB disease in
both lungs and spleen (mean (log10) in the lungs = 6.02 and
4.87 CFU for naı¨ve and BCG i.d. respectively). BCG delivered i.n.
conferred slightly but not statistically significantly better protection
in lungs compared to BCG i.d. This is in contrast to the results
observed in Figure 1E, a factor that could be attributed to a
variable effect dependent on factors such as time post-vaccination
(10 weeks vs. 14 weeks) or M.tb challenge dose. The same was
observed for animals vaccinated with BCG – MVA85A. When CT
was administered along with BCG prior to MVA85A (BCG + CT
– MVA85A), there were lower bacterial counts in both lungs and
CT-Enhanced Protection against Murine TB
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spleen compared to BCG – MVA85A, and these reached
significance in the lungs and spleen (for lung: mean (log10)
= 4.39 and 4.04 CFU for BCG – MVA85A only and CT-treated
respectively; for spleen: mean = 3.50 and 2.81 CFU for BCG –
MVA85A and CT-treated respectively).
We next attempted to block the improved protection conferred
by CT co-administration using an anti-IL-17A blocking antibody,
administered intraperitoneally every three days post-challenge for
four weeks. The following groups received the blocking antibody:
BCG – MVA85A and BCG + CT – MVA85A, all administered
i.n. A group vaccinated with BCG – MVA85A received an IgG2A
isotype control antibody.
As in the first experiment, BCG + CT – MVA85A significantly
enhanced protection against aerosol challenge (Fig 2D; mean
(log10) = 4.77 and 4.12 CFU for BCG – MVA85A and CT-
treated respectively). Administration of the isotype control
antibody did not significantly affect the lung CFU indicating that
any difference seen in the antibody-treated groups can be
attributed to the antibody’s specificity (mean (log10) = 4.77 and
4.74 CFU for no antibody and isotype respectively). Comparing
the BCG – MVA85A group receiving antibody and the group
receiving the isotype control, the lung CFU was higher in the anti-
IL-17-treated group, although this difference was not statistically
significant using ANOVA followed by Bonferroni’s multiple
comparison post-test (mean (log10) = 4.74 and 5.14 CFU for
isotype and anti-IL-17 respectively). A similar trend was observed
in animals receiving BCG + CT – MVA85A with the anti-IL-17
antibody compared to BCG + CT – MVA85A alone (mean (log10)
= 4.12 and 4.42 CFU for no antibody and anti-IL-17 treatment,
respectively).
Lung pathology is not adversely affected following CT
treatment
Interleukin 17 is a highly inflammatory cytokine implicated as a
negative factor in many inflammatory diseases such as multiple
sclerosis, psoriasis and rheumatoid arthritis [27-29]. Aside from
transient illness immediately after vaccination, no adverse effects
were observed in animals receiving CT following M.tb challenge,
however it was important to examine the lungs of the challenged
animals in order to investigate the effects of the CT-induced IL-17
on lung pathology. One lung lobe was dissected from four animals
in each group at the experimental endpoint (four weeks post-
infection) and haematoxylin and eosin staining was used to
examine the inflammatory state of the lung. Section images were
cropped so that no white space was visible surrounding the section
(,30% of the image) as shown in Figure 3A.
Cropped sections were analysed using a k-means clustering
algorithm in MATLAB in order to determine the percentage of
the section represented by each of the following colours: purple
(nuclei), pink (red blood cells and cytoplasm) and white (space for
gas exchange). A sample of the resulting image in comparison to
the original is shown in Figure 3B. Representative images from
each group are shown in Figure 3C. Figure 3D shows the
percentages of each ‘colour’ for each of the groups. Although
numbers were too low to perform statistical analysis, there is a
trend towards a decrease in cell infiltrate (as measured by %
nuclei, and % red blood cells and cytoplasm) with a decrease in
lung CFU, and an increase in airspace along with a decrease in
lung CFU. Thus, the animals receiving CT had lower levels of cell
infiltrate and more airspace compared with unvaccinated animals
and animals receiving less effective vaccine regimens. None of
these yielded a significant correlation when tested (data not
shown).
Discussion
Experiments described in this paper aimed to explore the use of
CT as a proof-of-concept IL-17-inducing adjuvant in both BCG
and BCG – MVA85A vaccine regimens with the aim of boosting
IL-17 production by CD4+ T cells and investigating the resulting
effects on vaccine efficacy in an M.tb aerosol challenge model.
Study of vaccine-induced immunogenicity showed that CT
administered i.n. along with BCG was able to induce high levels
of IL-17 post-BCG in lungs and spleen. Furthermore, the
immunogenicity of BCG – MVA85A was also boosted by co-
administration of CT with the BCG prime. Following M.tb
challenge, mice receiving BCG + CT (6 MVA85A) had lower
lung and spleen CFU compared to the animals receiving non-
adjuvanted BCG. The effect in the lungs could be partially blocked
by an anti-IL-17 blocking antibody administered post-challenge,
supporting the already-published theory of a role for IL-17 in
vaccine-mediated protection against TB disease [3,4,30]. Although
not investigated here, other cytokines involved in the IL-17
pathway, such as IL-23, IL-21 and IL-22 are likely also
upregulated by CT treatment and it is probable that these also
play a role in protection following M.tb infection. Further work
should define comprehensively the cytokine profile induced by
CT. This work demonstrates a protective effect of IL-17 against
short-term challenge. Further work is merited to evaluate the
durability of this effect.
Given the delivery of BCG via the intranasal route, there could
be some residual BCG presence in the lungs even 14-18 weeks
following administration. This might confound the results both in
terms of residual BCG contributing to the immune response to an
M.tb challenge, and in terms of BCG being detected on the agar
plates used to determine bacterial burden. M.tb-specific agar plates
were not utilised in these experiments, however we would expect
the levels of BCG present in the lungs to be equal across the
groups, thus cancelling out this potential effect.
Adverse effects on lung pathology are a concern accompanying
any study involving boosting of IL-17, due to its highly
inflammatory profile. Work shown here suggests that establish-
ment of a chronic infection in the lungs of animals vaccinated with
a regimen shown to boost IL-17 has no adverse effects on lung
pathology, however more work is needed to confirm this. In these
experiments, although not statistically significant, lung pathology
was improved with the use of a regimen that reduced increased
Figure 1. Effect of cholera toxin on BCG immunogenicity and M.tb challenge outcome. (A) Cytokine gating in spleens and lungs,
unstimulated vs. Ag85A peptide pool-stimulated. (B) Balb/c mice received 46105 CFU BCG i.n. or i.d. followed 10 weeks later by 16106 PFU MVA85A
i.d. At weeks 10, 11 and 14 post-BCG, lungs were examined for cytokine production by ICS following Ag85A peptide pool stimulation in the presence
of Brefeldin A and GolgiStop. (C & D) Balb/c mice received 46105 CFU BCG62 mg CT i.n. After 10 weeks, lungs and spleen were dissected and
stimulated with PPD in the presence of Brefeldin A and GolgiStop. Percentages of CD4+ T cells producing IFN-c and IL-17 were calculated following
ICS on lung cells (C) and splenocytes (D). Mice receiving BCG only are plotted with closed circles and those receiving CT have open circles. P values
were calculated using a Mann Whitney test (n = 5). (E) Ten weeks post-BCG, mice received ,100 CFU M.tb via aerosol and four weeks later lungs and
spleen were homogenised and plated out for CFU quantitation. Statistical analysis was performed using a one way ANOVA and post-hoc tests on the
vaccinated groups (n = 8).
doi:10.1371/journal.pone.0078312.g001
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Figure 2. Immunogenicity and protective efficacy of BCG + CT – MVA85A. Balb/c mice received BCG6CT i.n. followed by 16106 CFU
MVA85A 10 weeks later. Lungs (A) and spleen (B) were taken at 10 (black circles), 11 (dark grey circles) and 14 (light grey circles) weeks post-BCG and
cytokine-producing cells responding to an Ag85A peptide pool quantified using ICS. Responses from animals receiving BCG – MVA85A (closed circles)
were compared with those receiving BCG + CT followed by MVA85A (open circles). Statistical analysis was performed using a Mann Whitney test.
n = 10, five each from two experiments. (C) Balb/c mice were vaccinated as above. Control groups included unvaccinated and BCG i.d. A group
receiving BCG i.n. was included to compare BCG – MVA85A i.n. to BCG i.n. Animals were exposed to ,100 CFU M.tb via aerosol four weeks post-
MVA85A. Four weeks post-challenge, lungs and spleen were homogenised and plated for CFU quantitation. (D) Balb/c mice were vaccinated and
challenged as described above. Groups receiving BCG – MVA85A and BCG + CT – MVA85A received an anti-IL-17 blocking antibody (MAB421; R&D
Systems) administered i.p. every three days post-challenge. One group receiving BCG – MVA85A received an IgG2a isotype control antibody (MAB006;
R&D Systems) on the same regimen. Mice were culled four weeks post-challenge and lung CFU quantitated as described above. Statistical analysis
was performed using a one way ANOVA and post-hoc tests on the vaccinated groups (n = 8–16).
doi:10.1371/journal.pone.0078312.g002
CT-Enhanced Protection against Murine TB
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levels of IL-17 pre-challenge and resulted in decreased bacterial
load in the lungs.
Although CT is not an adjuvant suitable for use in humans due
to its strong inflammatory nature and reported side effects,
including possible neurological symptoms [21], its use in animal
models is a valuable tool for studying a) the outcomes of such a
potent IL-17-inducing adjuvant, and b) mechanisms that could be
targeted to achieve a similar results. We have shown here that CT
given at the time of a mucosal BCG prime is an adjuvant capable
of improving vaccine-induced protection against murine M.tb
challenge. Cholera toxin acts through the cAMP pathway, thus
implicating this pathway as a potential target for adjuvants
designed to be given with BCG either as a vaccine on its own or as
a prime for a boosting vaccine such as MVA85A. Extracellular
ATP is a potential molecule that could be explored for this
purpose. Recent data has shown that mice lacking the ATP
Figure 3. Histological analysis of M.tb-exposed lungs. Four Balb/c mice from each group shown in Figure 2C had one lung lobe inflated with
10% NBF and dissected. Lungs were embedded in paraffin, sectioned, mounted onto slides and stained with haematoxylin and eosin. Images were
cropped so that no external white space was visible (A). Analysis was performed using a k means clustering algorithm in MATLAB (B). (C)
Representative sections from each group. (D) Percentages of the image represented by one of three colours (purple, red or white) were calculated
and plotted, n = 2-4.
doi:10.1371/journal.pone.0078312.g003
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receptor P2X7 have worsened disease following M.tb challenge
through a decrease in P2X7-mediated phago-lysosomal fusion
[31]. Furthermore, P2X7 activation through ATP binding
activates the NALP3 inflammasome, reviewed in [32], and ATP
can also bind to the P2Y11 receptor [33], activating the cAMP
pathway, both of which lead to induction of IL-17-inducing
cytokines and could be exploited for induction of a protective
immune response.
In conclusion, these data suggest that further evaluation of the
mechanisms of improved protection in mice in parallel with
evaluation of the mucosal route of vaccination and IL-17-inducing
adjuvants is merited in humans.
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